Doctor’s Search for Cure Brings New Hope to Patients With Rare Blood Disorder

Pomalidomide, a bone marrow cancer drug, may be safely repurposed to treat a rare genetic blood disorder, according to a recent clinical trial. The Cleveland Clinic-led clinical trial was stopped early after demonstrating safety and effectiveness in treating hereditary hemorrhagic telangiectasia (HHT), a condition that currently has no cure. Dr. Keith McCrae, professor of molecular medicine at the Cleveland Clinic who led the clinical trial, told The Epoch Times that he was motivated to find a drug for a particular patient he had 15 years ago. “This particular client was extremely ill…was requiring tens of thousands of dollars worth of blood products every week and was essentially advised to have most of his intestine resected because he was bleeding there,” McCrae said....